Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension.

By N. Nagaya, T. Nishikimi, M. Uematsu, T. Satoh, S. Kyotani, F. Sakamaki, M. Kakishita, K. Fukushima, Y. Okano, N. Nakanishi and 2 more. Circulation, 2000

837 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Right Ventricular Function in Cardiovascular Disease, Part I: Anatomy, Physiology, Aging, and Functional Assessment of the Right Ventricle (2008, neutral): “83 The hemodynamic improvement seen with nitric oxide was most likely secondary to selective pulmonary vasodilatation, resulting in a reduction in RV afterload and subsequent improvement in RV performance.”
Natriuretic peptides. (2007, background): “This scenario can be een in severe chronic obstructive pulmonary disease, priary pulmonary hypertension, and other causes of pulmoary hypertension (28,30,31).”
Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. (2007, background): “More promising is a rise in BNP that has shown to be related to poor outcome.(20,21) Our results showed that an increased RVEDV and especially progressive RV dilatation during treatment, are predictors of a poor survival.”
State of the art: Using natriuretic peptide levels in clinical practice (2008, background): “It appears that ACE inhibitors, angiotensin receptor blockers, spironolactone, and perhaps long-term beta-blockers (in the short-term beta-blockers increase NP levels) drive NP levels down [8–93].”